{
  "docId": "019de070-5583-7544-b7b3-e17a9a5a1395",
  "docSlug": "6e951aba00c366c61ecceffedb425cf6",
  "documentTitle": "Alkermes | Results Presentation Deck | 12 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 12,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5583-7544-b7b3-e17a9a5a1395/11",
  "deckHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395",
  "deckJsonHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395.json",
  "deckAnchorHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.185,
        "w": 0.914,
        "x": 0.043,
        "y": 0.258
      },
      "kind": "list",
      "text": "ARTISTRY-1 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress included evidence of ALKS 4230 antitumor activity, both as monotherapy and in combination with pembrolizumab, with durable and deepening responses observed in a diverse set of difficult-to-treat tumor types",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78bc9b5d-da60-4a7e-aea1-64c4ff32fd6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.884,
        "x": 0.073,
        "y": 0.567
      },
      "kind": "list",
      "text": "Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November will include pharmacokinetic, pharmacodynamic, safety and tolerability data from the initial dose escalation cohorts",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdf94dd0-d3cd-45fb-bc96-88958af8d3d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.052,
        "w": 0.891,
        "x": 0.043,
        "y": 0.462
      },
      "kind": "list",
      "text": "ARTISTRY-2 dose escalation is ongoing for both once-weekly and once-every-three-week subcutaneous dosing regimens",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea72b409-4430-4b70-b8c1-d93d1b061ffb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.052,
        "w": 0.786,
        "x": 0.037,
        "y": 0.096
      },
      "kind": "title",
      "text": "ALKS 4230: Advancing the Clinical Development Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab4f8608-f505-46d1-9f40-e4eae4ab6263",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "70ca517a-6afd-46d6-9f89-1b42c3cb2e5e",
      "evidence": "list/bullet: ARTISTRY-1 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress included evidence of ALKS 4230 antitumor activity, both as monotherapy and in combination with pembrolizumab, wi",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "94edb19a-9396-4c6b-b305-a4b726bf7dfa",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The closing ask slide prompts action from investors",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "0ec68cac-f7a5-4f84-b922-d55e9fbb1bb3",
      "evidence": "The ALKS 3831 and ALKS 4230 update slides show progress",
      "position": 1,
      "objective": "Updating on clinical development progress",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}